Company / Accounts Receivable
TG Therapeutics, Inc. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$305.6M
FY2025
5-year range
$0 / $305.6M
FY2022-FY2025
Trend
+136.6%
vs FY2024
Sector context
#28 of 113
Health Care
What the data says
TG Therapeutics, Inc.'s accounts receivable of $306M is higher than 75% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $0 in FY2022 to $306M in FY2025.
Based on SEC 10-K filings.
$306M in FY2025. Top quartile in the Health Care sector.
Improved from $51M to $306M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 113This company $305.6M Sector average $1.1B
▼
-73.1% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 136.6% year-over-year.
- Ranks #28 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $305.6M | +136.6% |
| FY2024 | $129.2M | +152.8% |
| FY2023 | $51.1M | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026